Three Analysts Offer Divergent Views on Thermo Fisher Scientific
Thermo Fisher Scientific (TMO) has drawn conflicting assessments from three analysts, with CLSA and UBS upgrading the stock while Bernstein maintains a hold. The divergence centers around whether the company's growth reacceleration is durable enough to justify current valuations. CLSA initiated coverage at Outperform on September 3 with a $748 target price, followed by UBS upgrading from Neutral to Buy on September 9 and raising its target to $730. Bernstein kept its Hold rating at $575, arguing the stock may already be priced for recovery. CEO Marc Casper highlighted during a Morgan Stanley conference that biotech funding is translating into spending across clinical research and lab supplies, supporting long-term growth expectations. He also noted positive developments in China's biotech sector and reshoring trends as potential upside drivers not fully reflected in current guidance. Thermo Fisher reported strong Q2 results with $11.99 billion revenue (up 10.5% YoY) and raised full-year guidance, reinforcing the bull case. The Street mean target price is around $645, masking underlying disagreement about future performance. UBS's upgrade was attributed to a new analyst assuming coverage rather than an internal reversal.
Tickers: $TMO
Topics: analysts growth expectations stock upgrades Thermo Fisher